Back to Results
| First Page | Meta Content | |
|---|---|---|
 | Document Date: 2015-03-23 21:11:42Open Document File Size: 168,79 KBShare Result on FacebookCompanyHuman Services / Alexion Pharmaceuticals Australasia Pty Ltd / Restrictions Working Group / /CountryAustralia / /EventFDA Phase / /IndustryTermclinical algorithms / clinical management algorithms / treatment of atypical Haemolytic Uraemic Syndrome / treatment algorithm / chronic dialysis / clinical treatment algorithms / /MedicalConditiontherapy-Sensitive Atypical Hemolytic Uremic Syndrome / chronic end stage renal disease / atypical haemolytic syndrome / proteinuria / chronic dialysis / b All / disease / end stage renal failure / Severe Acquired ADAMTS13 Deficiency / chronic renal failure / ESRD / thrombotic thrombocytopenic purpura / chronic dialysis group / heterogeneous disease / severe inflammation / blood clots / chronic kidney / chronic kidney disease / chronic dialysis demonstrating / Atypical Hemolytic Uremic Syndrome / atypical Haemolytic Uraemic Syndrome / atypical haemolytic-uremic syndrome / STEC infection / renal disease / thrombotic thrombocytopenia purpura / infection / Plasma TherapyResistant Atypical Hemolytic Uremic Syndrome / end stage renal disease / severe disease / long disease duration / chronic conditions / /MedicalTreatmentplasma exchange / kidney transplant / dialysis / renal transplant / /OrganizationPharmaceutical Benefits Advisory Committee / Multi-Centre Controlled Clinical Trial / Department of Human Services / American Society / Australian Government / American Society of Nephrology / /Positionrepresentative of the first group / /ProductSoliris / C08-002 / /Technologytreatment algorithm / two clinical management algorithms / antibodies / 19 Trial ID Protocol / two clinical treatment algorithms / two algorithms / dialysis / /SocialTag |